Drug Safety

, Volume 25, Issue 4, pp 263–286 | Cite as

Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes

An Overview
  • Fabrizio De Ponti
  • Elisabetta Poluzzi
  • Andrea Cavalli
  • Maurizio Recanatini
  • Nicola Montanaro
Review Article


The long and growing list of non-antiarrhythmic drugs associated with prolongation of the QT interval of the electrocardiogram has generated concern not only for regulatory interventions leading to drug withdrawal, but also for the unjustified view that QT prolongation is usually an intrinsic effect of a whole therapeutic class [e.g. histamine H1 receptor antagonists (antihistamines)], whereas, in many cases, it is displayed only by some compounds within a given class of non-antiarrhythmic drugs because of an effect on cardiac repolarisation. We provide an overview of the different classes of non-antiarrhythmic drugs reported to prolong the QT interval (e.g. antihistamines, antipsychotics, antidepressants and macrolides) and discusses the clinical relevance of the QT prolonging effect. Drug-induced torsade de pointes are sometimes considered idiosyncratic, totally unpredictable adverse drug reactions, whereas a number of risk factors for their occurrence is now recognised. Widespread knowledge of these risk factors and implementation of a comprehensive list of QT prolonging drugs becomes an important issue. Risk factors include congenital long QT syndrome, clinically significant bradycardia or heart disease, electrolyte imbalance (especially hypokalaemia, hypomagnesaemia, hypocalcaemia), impaired hepatic/renal function, concomitant treatment with other drugs with known potential for pharmacokinetic/pharmacodynamic interactions (e.g. azole antifungals, macrolide antibacterials and class I or III antiarrhythmic agents). This review provides insight into the strategies that should be followed during a drug development program when a drug is suspected to affect the QT interval. The factors limiting the predictive value of preclinical and clinical studies are also outlined.

The sensitivity of preclinical tests (i.e. their ability to label as positive those drugs with a real risk of inducing QT pronglation in humans) is sufficiently good, but their specificity (i.e. their ability to label as negative those drugs carrying no risk) is not well established. Verapamil is a notable example of a false positive: it blocks human ether-a-go-go-related (HERG) K+ channels, but is reported to have little potential to trigger torsade de pointes. Although inhibition of HERG K+ channels has been proposed as a primary test for screening purposes, it is important to remember that several ion currents are involved in the generation of the cardiac potential and that metabolites must be specifically tested in this in vitro test. At the present state of knowledge, no preclinical model has an absolute predictive value or can be considered as a gold standard. Therefore, the use of several models facilitates decision making and is recommended by most experts in the field.



No funding was used to assist in conducting the study and the authors do not have any conflicts of interest directly relevant to the contents of the manuscript.


  1. 1.
    De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56: 1–18PubMedCrossRefGoogle Scholar
  2. 2.
    Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216–31PubMedCrossRefGoogle Scholar
  3. 3.
    European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CPMP): points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]. Available from URL: http://www.emea.eu.int/pdfs/human/swp/098696en.pdf [Accessed 2002 Apr 14]
  4. 4.
    Zhang MQ. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997; 4: 171–84Google Scholar
  5. 5.
    Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf 2001; 24: 119–47PubMedCrossRefGoogle Scholar
  6. 6.
    Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001; 61: 207–36PubMedCrossRefGoogle Scholar
  7. 7.
    Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122–6PubMedGoogle Scholar
  8. 8.
    Owens RCJ. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsade de pointes. Pharmacotherapy 2001; 21: 301–19PubMedCrossRefGoogle Scholar
  9. 9.
    Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 1007–12PubMedGoogle Scholar
  10. 10.
    Glassman AH, Bigger JTJ. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82PubMedCrossRefGoogle Scholar
  11. 11.
    Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24: 323–51PubMedCrossRefGoogle Scholar
  12. 12.
    Roden DM. Antiarrhythmic drugs. In: Hardman, Goodman Gilman, Limbird, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 2001: 839–874Google Scholar
  13. 13.
    Suessbrich H, Waldegger S, Lang F, et al. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385: 77–80PubMedCrossRefGoogle Scholar
  14. 14.
    Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54: 113–21PubMedGoogle Scholar
  15. 15.
    Bischoff U, Schmidt C, Netzer R, et al. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000; 406: 341–3PubMedCrossRefGoogle Scholar
  16. 16.
    Tie H, Walker BD, Valenzuela SM, et al. The heart of psychotropic drug therapy [letter]. Lancet 2000; 355: 1825PubMedCrossRefGoogle Scholar
  17. 17.
    Suessbrich H, Schonherr R, Heinemann SH, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120: 968–74PubMedCrossRefGoogle Scholar
  18. 18.
    Pond AL, Nerbonne JM. ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart. Trends Cardiovasc Med 2001; 11: 286–94PubMedCrossRefGoogle Scholar
  19. 19.
    Fedida D, Chen FS, Zhang X. The 1997 Stevenson Award Lecture. Cardiac K+ channel gating: cloned delayed rectifier mechanisms and drug modulation. Can J Physiol Pharmacol 1998; 76: 77–89PubMedGoogle Scholar
  20. 20.
    Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10: 272–82PubMedCrossRefGoogle Scholar
  21. 21.
    Vandenberg JI, Walker BD, Campbell TJ. HERGK(+) channels: friend and foe. Trends Pharmacol Sci 2001; 22: 240–6PubMedCrossRefGoogle Scholar
  22. 22.
    Shieh CC, Coghlan M, Sullivan JP, et al. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000; 52: 557–94PubMedGoogle Scholar
  23. 23.
    Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001; 110: 385–98PubMedCrossRefGoogle Scholar
  24. 24.
    Tseng GN. I(Kr): The hERG Channel. J Mol Cell Cardiol 2001; 33: 835–49PubMedCrossRefGoogle Scholar
  25. 25.
    Roden DM, George ALJ. Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997; 273:H511–25PubMedGoogle Scholar
  26. 26.
    Karagueuzian HS. Acquired long QT syndromes and the risk of proarrhythmia [letter]. J Cardiovasc Electrophysiol 2000; 11: 1298CrossRefGoogle Scholar
  27. 27.
    Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999; 6: 469–80Google Scholar
  28. 28.
    Nau C, Seaver M, Wang SY, et al. Block of human heart hH1 sodium channels by amitriptyline. J Pharmacol Exp Ther 2000; 292: 1015–23PubMedGoogle Scholar
  29. 29.
    Isenberg G, Tamargo J. Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. Eur J Pharmacol 1985; 108: 121–31PubMedCrossRefGoogle Scholar
  30. 30.
    Delpon E, Tamargo J, Sanchez-Chapula J. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1991; 344: 645–52PubMedCrossRefGoogle Scholar
  31. 31.
    Reich MR, Ohad DG, Overall KL, et al. Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration [published erratum appears in J Am Vet Med Assoc 2000 Jun 15; 216 (12): 1936]. J Am Vet Med Assoc 2000; 216: 1571–5PubMedCrossRefGoogle Scholar
  32. 32.
    Kennerdy A, Thomas P, Sheridan DJ. Generalized seizures as the presentation of flecainide toxicity. Eur Heart J 1989; 10: 950–4PubMedGoogle Scholar
  33. 33.
    Platia EV, Estes M, Heine DL, et al. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 1985; 55: 956–62PubMedCrossRefGoogle Scholar
  34. 34.
    Bruelle P, LeFrant JY, de La Coussaye JE, et al. Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs. Anesth Analg 1996; 82: 648–56PubMedGoogle Scholar
  35. 35.
    Sheridan DJ. Drug-induced proarrhythmic effects: assessment of changes in QT interval. Br J Clin Pharmacol 2000; 50: 297–302PubMedCrossRefGoogle Scholar
  36. 36.
    O’Leary ME. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol Pharmacol 2001; 59: 269–77PubMedGoogle Scholar
  37. 37.
    Zhang S, Rajamani S, Chen Y, et al. Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Mol Pharmacol 2001; 59: 1069–76PubMedGoogle Scholar
  38. 38.
    Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97: 10613–8PubMedCrossRefGoogle Scholar
  39. 39.
    Gamouras GA, Monir G, Plunkitt K, et al. Cocaine abuse: repolarization abnormalities and ventricular arrhythmias. Am J Med Sci 2000; 320: 9–12PubMedCrossRefGoogle Scholar
  40. 40.
    Parker RB, Perry GY, Horan LG, et al. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. J Cardiovasc Pharmacol 1999; 34: 864–9PubMedCrossRefGoogle Scholar
  41. 41.
    Wang RY. pH-dependent cocaine-induced cardiotoxicity. Am J Emerg Med 1999; 17: 364–9PubMedCrossRefGoogle Scholar
  42. 42.
    Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J 2001; 3Suppl.: K70–80Google Scholar
  43. 43.
    Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000; 320: 1158–9PubMedCrossRefGoogle Scholar
  44. 44.
    Wiener I, Rubin DA, Martinez E, et al. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. Mt Sinai J Med 1981; 48: 53–5PubMedGoogle Scholar
  45. 45.
    Lopez JA, Harold JG, Rosenthal MC, et al. QT prolongation and torsade de pointes after administration of trimethoprimsulfamethoxazole. Am J Cardiol 1987; 59: 376–7PubMedCrossRefGoogle Scholar
  46. 46.
    Zhou Z, Vorperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10: 836–43PubMedCrossRefGoogle Scholar
  47. 47.
    De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsade de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185–209PubMedCrossRefGoogle Scholar
  48. 48.
    Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole [letter]. Ann Intern Med 1999; 131: 797PubMedGoogle Scholar
  49. 49.
    Tholakanahalli VN, Potti A, Hanley JF, et al. Fluconazole-induced torsade de pointes. Ann Pharmacother 2001; 35: 432–4PubMedCrossRefGoogle Scholar
  50. 50.
    Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998; 286: 727–35PubMedGoogle Scholar
  51. 51.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–80PubMedCrossRefGoogle Scholar
  52. 52.
    Saarnivaara L, Hiller A, Oikkonen M. QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children. Acta Anaesthesiol Scand 1993; 37: 419–23PubMedCrossRefGoogle Scholar
  53. 53.
    Saarnivaara L, Klemola UM, Lindgren L, et al. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia. Acta Anaesthesiol Scand 1990; 34: 276–81PubMedCrossRefGoogle Scholar
  54. 54.
    Michaloudis DG, Kanakoudis FS, Petrou AM, et al. The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans. Eur J Anaesthesiol 1996; 13: 364–8PubMedCrossRefGoogle Scholar
  55. 55.
    Azzolini M, Ragagni M, Pfaender M, et al. La sindrome idiopatica del QT lungo. Variazioni della durata del QTc durante anestesia con propofol. Minerva Anestesiol 1993; 59: 377–80PubMedGoogle Scholar
  56. 56.
    Michaloudis D, Fraidakis O, Kanoupakis E, et al. Idiopathic prolonged QT interval and QT dispersion: the effects of propofol during implantation of cardioverter-defibrillator. Eur J Anaesthesiol 1999; 16: 842–7PubMedGoogle Scholar
  57. 57.
    Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhytmias associated with fexofenadine [letter]. Lancet 1999; 353: 980PubMedCrossRefGoogle Scholar
  58. 58.
    Yan GX, Wu Y, Liu T, et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-qt syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103: 2851–6PubMedCrossRefGoogle Scholar
  59. 59.
    Haverkamp W, Eckardt L, Mönnig G, et al. Clinical aspects of ventricular arrhythmias associated with QT prolongation. Eur Heart J 2001; 3Suppl.: K81–8Google Scholar
  60. 60.
    Morganroth J. Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J 2001; 3Suppl.: K105–11Google Scholar
  61. 61.
    Paltoo B, O’Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001; 24: 895–7PubMedCrossRefGoogle Scholar
  62. 62.
    Drici MD. Influence of gender on drug-acquired long QT syndrome. Eur Heart J 2001; 3Suppl.: K41–7Google Scholar
  63. 63.
    Drici MD, Clement N. Is gender a risk factor for adverse drug reactions?. The example of drug-induced long QT syndrome. Drug Saf 2001; 24: 575–85PubMedCrossRefGoogle Scholar
  64. 64.
    Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89–95PubMedCrossRefGoogle Scholar
  65. 65.
    Antzelevitch C. Heterogeneity of cellular repolarization in LQTS: the role of M cells. Eur Heart J 2001; 3Suppl.: K2–16Google Scholar
  66. 66.
    Yan GX, Rials SJ, Wu Y, et al. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early after depolarization. Am J Physiol 2001; 281: H1968–75Google Scholar
  67. 67.
    Kääb S, Näbauer M. Diversity of ion channel expression in health and disease. Eur Heart J 2001; 3Suppl.: K31–40Google Scholar
  68. 68.
    Curb JD, Rodriguez BL, Burchfiel CM, et al. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995; 91: 2591–5PubMedCrossRefGoogle Scholar
  69. 69.
    Brown DW, Giles WH, Greenlund KJ, et al. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk 2001; 8: 227–33PubMedCrossRefGoogle Scholar
  70. 70.
    Thompson R, Rich J, Chmelik F, et al. Evolutionary changes in the electrocardiogram of severe progressive hypothermia. J Electrocardiol 1977; 10: 67–70PubMedCrossRefGoogle Scholar
  71. 71.
    Mortensen E, Berntsen R, Tveita T, et al. Changes in ventricular fibrillation threshold during acute hypothermia. A model for future studies. J Basic Clin Physiol Pharmacol 1993; 4: 313–9PubMedCrossRefGoogle Scholar
  72. 72.
    Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28–34PubMedCrossRefGoogle Scholar
  73. 73.
    Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001; 6: 111–9PubMedCrossRefGoogle Scholar
  74. 74.
    Idle JR. The heart of psychotropic drug therapy. Lancet 2000; 355: 1824–5PubMedCrossRefGoogle Scholar
  75. 75.
    Bauman JL. The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome. Eur Heart J 2001; 3Suppl.: K93–100Google Scholar
  76. 76.
    Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 2000; 50: 77–80PubMedCrossRefGoogle Scholar
  77. 77.
    Murakawa Y, Yamashita T, Ajiki K, et al. Ostensible day-night difference of QT prolongation during long-term treatment with antiarrhythmic drugs: reappraisal of the law of ‘regression to the mean’. J Cardiovasc Pharmacol 1998; 32: 62–5PubMedCrossRefGoogle Scholar
  78. 78.
    Lande G, Kyndt F, Baro I, et al. Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype. Eur Heart J 2001; 22: 410–22PubMedCrossRefGoogle Scholar
  79. 79.
    Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96: 2778–81PubMedCrossRefGoogle Scholar
  80. 80.
    Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99: 529–33PubMedCrossRefGoogle Scholar
  81. 81.
    Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36: 1749–66PubMedCrossRefGoogle Scholar
  82. 82.
    Murray A, McLaughlin NB, Bourke JP, et al. Errors in manual measurement of QT intervals. Br Heart J 1994; 71: 386–90PubMedCrossRefGoogle Scholar
  83. 83.
    Fisch C. Centennial of the string galvanometer and the electrocardiogram. J Am Coll Cardiol 2000; 36: 1737–45PubMedCrossRefGoogle Scholar
  84. 84.
    Bonate PL, Russell T. Assessment of QTc prolongation for noncardiac-related drugs from a drug development perspective. J Clin Pharmacol 1999; 39: 349–58PubMedCrossRefGoogle Scholar
  85. 85.
    Bonate PL. Rank power of metrics used to assess QTc interval prolongation by clinical trial simulation. J Clin Pharmacol 2000; 40: 468–74PubMedCrossRefGoogle Scholar
  86. 86.
    Malik M. QT dispersion: time for an obituary? Eur Heart J 2000; 21: 955–7PubMedCrossRefGoogle Scholar
  87. 87.
    Krahn AD, Nguyen-Ho P, Klein GJ, et al. QT dispersion: an electrocardiographic derivative of QT prolongation. Am Heart J 2001; 141: 111–6PubMedCrossRefGoogle Scholar
  88. 88.
    Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411–20PubMedCrossRefGoogle Scholar
  89. 89.
    Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001; 43: 1–45PubMedGoogle Scholar
  90. 90.
    Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72: B17–22CrossRefGoogle Scholar
  91. 91.
    Aytemir K, Maarouf N, Gallagher MM, et al. Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 1999; 22: 1397–401PubMedCrossRefGoogle Scholar
  92. 92.
    Cavero I, Mestre M, Guillon JM, et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1: 947–73PubMedCrossRefGoogle Scholar
  93. 93.
    Puddu PE, Jouve R, Mariotti S, et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia’s equation. J Electrocardiol 1988; 21: 219–29PubMedCrossRefGoogle Scholar
  94. 94.
    Dabrowski A, Kramarz E, Kubik L. Prolongation of QT interval corrected for heart rate by Bazett’s equation and linear formula as predictor of arrhythmic events after myocardial infarction. Am J Cardiol 2000; 86: 469–72CrossRefGoogle Scholar
  95. 95.
    Volders PG, Vos MA, Szabo B, et al. Progress in the understanding of cardiac early afterdepolarizations and torsade de pointes: time to revise current concepts. Cardiovasc Res 2000; 46: 376–92PubMedCrossRefGoogle Scholar
  96. 96.
    Oberg KC, Bauman JL. QT interval prolongation and torsade de pointes due to erythromycin lactobionate. Pharmacotherapy 1995; 15: 687–92PubMedGoogle Scholar
  97. 97.
    Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000; 36: 1–12PubMedCrossRefGoogle Scholar
  98. 98.
    Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 691–6PubMedCrossRefGoogle Scholar
  99. 99.
    Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–7PubMedCrossRefGoogle Scholar
  100. 100.
    Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322–6PubMedCrossRefGoogle Scholar
  101. 101.
    Schwartz JB. The electrocardiographic QT interval and its prolongation in response to medications: differences between men and women. J Gend Specif Med 2000; 3: 25–8PubMedGoogle Scholar
  102. 102.
    Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsade de pointes. Pacing Clin Electrophysiol 1998; 21: 1029–34PubMedCrossRefGoogle Scholar
  103. 103.
    Darbar D, Fromm MF, Dellorto S, et al. Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol 2001; 12: 9–14PubMedCrossRefGoogle Scholar
  104. 104.
    Kitayama H, Kiuchi K, Nejima J, et al. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55: 259–62PubMedCrossRefGoogle Scholar
  105. 105.
    Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52PubMedCrossRefGoogle Scholar
  106. 106.
    Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 2000; 50: 247–53PubMedCrossRefGoogle Scholar
  107. 107.
    Saul JP, Ross B, Schaffer MS, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supra-ventricular and ventricular tachyarrhythmia. Clin Pharmacol Ther 2001; 69: 145–57PubMedCrossRefGoogle Scholar
  108. 108.
    Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000; 11: 938–40PubMedCrossRefGoogle Scholar
  109. 109.
    Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175–87PubMedCrossRefGoogle Scholar
  110. 110.
    Michiels M, Van Peer A, Woestenborghs R, et al. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8: 53–62CrossRefGoogle Scholar
  111. 111.
    Sugiyama A, Aye NN, Katahira S, et al. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 1997; 143: 89–95PubMedCrossRefGoogle Scholar
  112. 112.
    Netzer R, Ebneth A, Bischoff U, et al. Screening lead compounds for QT interval prolongation. Drug Discov Today 2001; 6: 78–84PubMedCrossRefGoogle Scholar
  113. 113.
    Champeroux P, Martel E, Vannier C, et al. The preclinical assessment of the risk for QT interval prolongation. Therapie 2000; 55: 101–9PubMedGoogle Scholar
  114. 114.
    Crumb W, Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 1999; 2: 270–80PubMedCrossRefGoogle Scholar
  115. 115.
    Puddu PE, Criniti A, Monti F. Screening for drug-induced (acquired) long QT syndrome: is it time to apply new methods? Eur Heart J 2001; 22: 363–9PubMedCrossRefGoogle Scholar
  116. 116.
    Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103: 2004–13PubMedCrossRefGoogle Scholar
  117. 117.
    Cavero I, Crumb-WJ J. Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs. Eur Heart J 2001; 3Suppl.: K53–63Google Scholar
  118. 118.
    Moise NS, Gilmour RFJ, Riccio ML. An animal model of spontaneous arrhythmic death. J Cardiovasc Electrophysiol 1997; 8: 98–103PubMedCrossRefGoogle Scholar
  119. 119.
    Surawicz B. U wave: facts, hypotheses, misconceptions, and misnomers. J Cardiovasc Electrophysiol 1998; 9: 1117–28PubMedCrossRefGoogle Scholar
  120. 120.
    Vila JA, Gang Y, Rodriguez PJ, et al. A new approach for TU complex characterization. IEEE Trans Biomed Eng 2000; 47: 764–72PubMedCrossRefGoogle Scholar
  121. 121.
    Ficker E, Jarolimek W, Kiehn J, et al. Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 1998; 82: 386–95PubMedCrossRefGoogle Scholar
  122. 122.
    Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000; 57: 367–74PubMedGoogle Scholar
  123. 123.
    Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000; 97: 12329–33PubMedCrossRefGoogle Scholar
  124. 124.
    Wermuth CG, Langer T. Pharmacophore Identification. In: Kubinyi H, editor. 3D QSAR in Drug Design. Theory, Methods and Applications. Leiden: ESCOM, 1993: 117–136Google Scholar
  125. 125.
    Morgan TKJ, Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem 1992; 29: 65–108PubMedCrossRefGoogle Scholar
  126. 126.
    Segarra V, Lopez M, Ryder H, et al. Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine. Drug Saf 1999; 21Suppl. 1: 45–61PubMedCrossRefGoogle Scholar
  127. 127.
    Hansch C. Quantitative structure-activity relationships and the unnamed science. Acc Chem Res 1993; 26: 147–53CrossRefGoogle Scholar
  128. 128.
    Podlogar BL, Ferguson DM. QSAR and CoMFA: a perspective on the practical application to drug discovery. Drug Des Discov 2000; 17: 4–12PubMedGoogle Scholar
  129. 129.
    Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Des 2001; 7: 567–97PubMedCrossRefGoogle Scholar
  130. 130.
    Finlayson K, Turnbull L, January CT, et al. [3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001; 430: 147–8PubMedCrossRefGoogle Scholar
  131. 131.
    Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res 1998; 39: 178–93PubMedCrossRefGoogle Scholar
  132. 132.
    Gintant GA, Limberis JT, McDermott JS, et al. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001; 37: 607–18PubMedCrossRefGoogle Scholar
  133. 133.
    Shimizu W, Antzelevitch C. Effects of a K+ channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000; 102: 706–12PubMedCrossRefGoogle Scholar
  134. 134.
    Yang T, Snyders D, Roden DM. Drug block of i kr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001; 38: 737–44PubMedCrossRefGoogle Scholar
  135. 135.
    Lu HR, Remeysen P, Somers K, et al. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 2001; 12: 538–45PubMedCrossRefGoogle Scholar
  136. 136.
    Volders PG, Sipido KR, Vos MA, et al. Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 1999; 100: 2455–61PubMedCrossRefGoogle Scholar
  137. 137.
    Yamamoto K, Tamura T, Imai R, et al. Acute canine model for drug-induced torsade de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol Sci 2001; 60: 165–76PubMedCrossRefGoogle Scholar
  138. 138.
    Van Opstal JM, Leunissen JD, Wellens HJ, et al. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of torsade de pointes arrhythmias. Eur J Pharmacol 2001; 412: 67–76PubMedCrossRefGoogle Scholar
  139. 139.
    Davis AS. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol 1998; 17: 677–80PubMedCrossRefGoogle Scholar
  140. 140.
    Carlsson L. Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J 2001; 3Suppl.: K114–20Google Scholar
  141. 141.
    Zhang S, Zhou Z, Gong Q, et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999; 84: 989–98PubMedCrossRefGoogle Scholar
  142. 142.
    Lacerda AE, Kramer J, Shen KZ, et al. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J 2001; 3Suppl.: K23–30Google Scholar
  143. 143.
    Rosen MR. Isolated tissue models and proarrhythmia. Eur Heart J 2001; 3Suppl.: K64–9Google Scholar
  144. 144.
    Escande D. Inhibition of repolarizing ionic currents by drugs. Eur Heart J 2001; 3Suppl.: K17–22Google Scholar
  145. 145.
    Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 2001; 49: 741–50PubMedCrossRefGoogle Scholar
  146. 146.
    Van de Water A, Verheyen J, Xhonneux R, et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989; 22: 207–17PubMedCrossRefGoogle Scholar
  147. 147.
    Matsunaga T, Mitsui T, Harada T, et al. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J Pharmacol Toxicol Methods 1997; 38: 201–9PubMedCrossRefGoogle Scholar
  148. 148.
    Spence S, Soper K, Hoe CM, et al. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxicol Sci 1998; 45: 247–58PubMedCrossRefGoogle Scholar
  149. 149.
    Classen W, Altmann B, Gretener P, et al. Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs. Exp Toxicol Pathol 1999; 51: 507–16PubMedCrossRefGoogle Scholar
  150. 150.
    Davis AS, Middleton BJ. Relationship between QT interval and heart rate in Alderley Park beagles. Vet Rec 1999; 145: 248–50PubMedCrossRefGoogle Scholar
  151. 151.
    Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353–70Google Scholar
  152. 152.
    Molnar J, Weiss JS, Rosenthal JE. The missing second: what is the correct unit for the Bazett corrected QT interval? Am J Cardiol 1995; 75: 537–8PubMedCrossRefGoogle Scholar
  153. 153.
    Moss AJ. Correct the QT interval correctly: QTc should be expressed in the same unit as the QT interval. Pacing Clin Electrophysiol0 1996; 19: 881–2PubMedCrossRefGoogle Scholar
  154. 154.
    Gralinski MR. The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. J Pharmacol Toxicol Methods 2000; 43: 91–9PubMedCrossRefGoogle Scholar
  155. 155.
    Fridericia LS. Die sytolendauer in elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920; 53: 469–86CrossRefGoogle Scholar
  156. 156.
    Matsunaga T, Mitsui T, Harada T, et al. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J Pharmacol Toxicol Methods 1997; 38: 201–9PubMedCrossRefGoogle Scholar
  157. 157.
    Matsunaga T, Harada T, Inokuma M, et al. QT prolongation and torsade de pointes induced by an antifungal agent, D0870, in conscious dogs. Toxicology 1999; 132: 187–99PubMedCrossRefGoogle Scholar
  158. 158.
    Moss AJ, Zareba W, Benhorin J, et al. ISHNE Guidelines for Electrocardiographic Evaluation of Drug-Related QT Prolongation and Other Alterations in Ventricular Repolarization: Task Force Summary. A report of the task force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol 2001; 6: 333–41PubMedCrossRefGoogle Scholar
  159. 159.
    Malik M, Acar B, Gang Y, et al. QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization. J Cardiovasc Electrophysiol 2000; 11: 835–43PubMedCrossRefGoogle Scholar
  160. 160.
    Sahu P, Lim PO, Rana BS, et al. QT dispersion in medicine: electrophysiological holy grail or fool’s gold? Q J Med 2000; 93: 425–31CrossRefGoogle Scholar
  161. 161.
    Lombardi F. Qt dispersion: an inappropriate measure of a good concept. Int J Cardiol 2001; 77: 148–9CrossRefGoogle Scholar
  162. 162.
    De Ponti F, Poluzzi E, Ferguson J, et al. Exposure to non-cardiac QT-prolonging drugs in the community: comparison among seven countries [abstract]. Pharmacoepidemiol Drug Saf 2000; 9Suppl. 1: S16Google Scholar
  163. 163.
    Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036–9PubMedCrossRefGoogle Scholar
  164. 164.
    Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001; 285: 1840–1PubMedCrossRefGoogle Scholar
  165. 165.
    Bianchi Weatherby L, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘Dear Doctor’ letters. Pharmacoepidemiol Drug Saf 2001; 10: 211–8CrossRefGoogle Scholar
  166. 166.
    McMullin ST, Reichley RM, Watson LA, et al. Impact of a web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med 1999; 159: 2077–82PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Fabrizio De Ponti
    • 1
  • Elisabetta Poluzzi
    • 1
  • Andrea Cavalli
    • 2
  • Maurizio Recanatini
    • 2
  • Nicola Montanaro
    • 1
  1. 1.Department of PharmacologyI-40126 University of BolognaBologna, 48Italy
  2. 2.Department of Pharmaceutical SciencesUniversity of BolognaBolognaItaly

Personalised recommendations